Clinical application of immune checkpoints in targeted immunotherapy of prostate cancer.
Biomarkers
Clinical trials
Co-inhibitory
Co-stimulatory
Monoclonal antibody
Journal
Cellular and molecular life sciences : CMLS
ISSN: 1420-9071
Titre abrégé: Cell Mol Life Sci
Pays: Switzerland
ID NLM: 9705402
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
17
07
2019
accepted:
10
01
2020
revised:
27
12
2019
pubmed:
2
2
2020
medline:
3
10
2020
entrez:
2
2
2020
Statut:
ppublish
Résumé
Immunotherapy is considered as an effective method for cancer treatment owing to the induction of specific and long-lasting anti-cancer effects. Immunotherapeutic strategies have shown significant success in human malignancies, particularly in prostate cancer (PCa), a major global health issue regarding its high metastatic rates. In fact, the first cancer vaccine approved by FDA was Provenge, which has been successfully used for treatment of PCa. Despite the remarkable success of cancer immunotherapy in PCa, many of the developed immunotherapy methods show poor therapeutic outcomes. Immunosuppression in tumor microenvironment (TME) induced by non-functional T cells (CD4
Identifiants
pubmed: 32006051
doi: 10.1007/s00018-020-03459-1
pii: 10.1007/s00018-020-03459-1
doi:
Substances chimiques
Antibodies, Monoclonal
0
B7-H1 Antigen
0
CTLA-4 Antigen
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM